Thomas Pieber

Thomas Pieber is Professor of Medicine, Chair of the Division of Endocrinology and Diabetology at the Department of Internal Medicine at Medical University of Graz in Austria. He is also Director of the Institute HEALTH – Institute for Biomedical Research and Technologies at Joanneum Research in Graz and founder of CBmed, a competence centre for biomarker research.

Thomas Pieber and his group have developed and tested several new therapeutic concepts for the type1 and type 2 diabetes, from new pharmacological interventions to innovative medical devices. In the recent years his research focus expanded to biomarker research in oncology and cardiovascular disease, to strategies for disease prevention and to digitalization in health care. Thomas Pieber was and currently is principal investigator (PI) in several international study groups and multicenter trials funded by the EU Commission and foundations such as JDRF and LRA in the USA. In INNODIA, a project funded by the EU Commission, Dr. Pieber is PI of the largest investigator-initiated study, the Ver-A-T1D trial, which investigates mechanisms of ß-cell protection in type 1 diabetes. In basic research he and his team investigate the role of metabolism in aging and ß-cell resilience.

Professor Pieber has written more than 450 original papers and reviews in peer-reviewed journals. He is a member of the International Working Group on the Diabetic Foot and a member of the Cochrane Review Group “Endocrine and Metabolic Diseases”. Furthermore, he serves as reviewer or advisor for international journals and funding organizations.